Themis signs manufacturing/supply deal with Novartis for TPM/diclofenac gel

On 12th April, Phosphagenics' commercial partner, Themis Medicare, entered into a licence and supply agreement with Novartis India, in which Themis will manufacture and supply diclofenac topical gel formulated using Phosphagenics' Targeted Penetration Matrix (TPM) transdermal drug-delivery system, to Novartis. The drug-delivery system is available only with Themis in India.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: India, India, India, India

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.